Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
ConclusionsThis large-scale, real-world, post-marketing surveillance study confirmed the safety and efficacy of abiraterone acetate plus prednisolone in Japanese castration-resistant prostate cancer patients with or without previous chemotherapy.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Japan Health | Prednisolone | Prostate Cancer | Study